Clinical trial

Incidence of Diabetes After a COVID-19 Infection

NCT05524792

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention no interventional study Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Incidence of Diabetes After a COVID-19 Infection

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2018-01-01

PhaseN/A

Conditions

COVID-19verified · MONDO: COVID-19

Diabetes Mellitusverified · MONDO: diabetes mellitus

Interventions

no interventional studyOTHER

Sponsors & collaborators

InGef - Institute for Applied Health Research Berlin GmbHlead sponsor

Robert Koch Institutcollaborator

Center for Evidence-Based Healthcare, Technische Universität Dresdencollaborator

Techniker Krankenkassecollaborator

BARMERcollaborator

DAK Gesundheitcollaborator

AOK PLUScollaborator

Vandage GmbHcollaborator

IKK Classiccollaborator

Mapped research locations

DresdenGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05524792 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.